Patents by Inventor Arthur E. Warrington
Arthur E. Warrington has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20220135659Abstract: The invention provides methods for the treatment of neonatal hypoxia and associated white matter disease or injury, particularly in infant, including neonatal, animals, particularly Periventricular Leukomalacia (PVL) comprising administering one or more CNS reactive antibody, particularly selected from IgM12, IgM22, IgM42 and IgM46. Compositions for use in treatment of white matter disease or injury in infants, particularly PVL are provided. The invention provides methods for alleviation of neuromotor or neurodevelopmental deficits associated with neonatal hypoxia and associated white matter injury, including PVL, in an infant.Type: ApplicationFiled: October 18, 2021Publication date: May 5, 2022Inventors: Jens O. Watzlawik, Arthur E. Warrington, Moses Rodriguez, William A. Carey
-
Patent number: 11180543Abstract: The invention provides methods for the treatment of neonatal hypoxia and associated white matter disease or injury, particularly in infant, including neonatal, animals, particularly Periventricular Leukomalacia (PVL) comprising administering one or more CNS reactive antibody, particularly selected from IgM12, IgM22, IgM42 and IgM46. Compositions for use in treatment of white matter disease or injury in infants, particularly PVL are provided. The invention provides methods for alleviation of neuromotor or neurodevelopmental deficits associated with neonatal hypoxia and associated with white matter injury, including PVL, in an infant.Type: GrantFiled: November 6, 2015Date of Patent: November 23, 2021Assignee: Mayo Foundation For Medical Education and ResearchInventors: Jens O. Watzlawik, Arthur E. Warrington, Moses Rodriguez, William A. Carey
-
Publication number: 20200397898Abstract: Specific binding members, particularly human antibodies, particularly recombinant antibodies, and fragments thereof, which are capable of binding to and recognizing neurons in the CNS and eliciting responses in CNS neurons are provided. The antibodies are useful for neuroprotection and in the diagnosis and treatment of conditions associated with nerve damage, injury or degeneration and neurodegenerative disease. The antibodies, variable regions or CDR domain sequences thereof, and fragments thereof of the invention may also be used in therapy in combination with chemotherapeutics, immune modulators, or neuroactive agents and/or with other antibodies or fragments thereof. Antibodies are exemplified by the antibodies IgM12 and IgM42 whose sequences are provided herein.Type: ApplicationFiled: May 7, 2020Publication date: December 24, 2020Inventors: Moses Rodriguez, Arthur E. Warrington, Larry R. Pease
-
Publication number: 20200247883Abstract: Antibodies, and particularly human antibodies, are disclosed that demonstrate activity in the treatment of demyelinating diseases as well as other diseases of the central nervous system that are of viral, bacterial or idiopathic origin, including neural dysfunction caused by spinal cord injury. Neuromodulatory agents are set forth that include and comprise a material selected from the group consisting of an antibody capable of binding structures or cells in the central nervous system, a peptide analog, a hapten, active fragments thereof, agonists thereof, mimics thereof, monomers thereof and combinations thereof. Methods are described for treating demyelinating diseases, and diseases of the central nervous system of humans and domestic animals, using polyclonal IgM antibodies and human monoclonal antibodies sHIgm22(LYM 22), sHIgm46(LYM46) ebvHIgM MSI19D10, CB2bG8, AKJR4, CB2iE12, CB2iE7, MSI19E5 and MSI10E10, active fragments thereof and the like.Type: ApplicationFiled: September 23, 2019Publication date: August 6, 2020Inventors: Elliott A. Gruskin, Arthur E. Warrington, Allan J. Bieber, Moses Rodriguez, Eric Walter Theodore Chojnicki
-
Publication number: 20180179277Abstract: Antibodies, and particularly human antibodies, are disclosed that demonstrate activity in the treatment of demyelinating diseases as well as other diseases of the central nervous system that are of viral, bacterial or idiopathic origin, including neural dysfunction caused by spinal cord injury. Neuromodulatory agents are set forth that include and comprise a material selected from the group consisting of an antibody capable of binding structures or cells in the central nervous system, a peptide analog, a hapten, active fragments thereof, agonists thereof, mimics thereof, monomers thereof and combinations thereof. Methods are described for treating demyelinating diseases, and diseases of the central nervous system of humans and domestic animals, using polyclonal IgM antibodies and human monoclonal antibodies sHIgm22(LYM 22), sHIgm46(LYM46) ebvHIgM MSI19D10, CB2bG8, AKJR4, CB2iE12, CB2iE7, MSI19E5 and MSI10E10, active fragments thereof and the like.Type: ApplicationFiled: September 1, 2017Publication date: June 28, 2018Inventors: Elliott A. Gruskin, Arthur E. Warrington, Allan J. Bieber, Moses Rodriguez, Eric Walter Theodore Chojnicki
-
Patent number: 9981019Abstract: This document relates to methods and materials involved in treating and/or preventing and/or reducing the severity of a viral infection present in a mammal. For example, methods and materials for reducing the severity of a viral infection present in a mammal (e.g., a human) are provided.Type: GrantFiled: July 28, 2016Date of Patent: May 29, 2018Assignee: Mayo Foundation for Medical Education and ResearchInventors: Moses Rodriguez, Allan J. Bieber, Arthur E. Warrington, Jr., Meghan McGee Painter, Eric M. Poeschla
-
Publication number: 20170355754Abstract: The invention provides methods for the treatment of neonatal hypoxia and associated white matter disease or injury, particularly in infant, including neonatal, animals, particularly Periventricular Leukomalacia (PVL) comprising administering one or more CNS reactive antibody, particularly selected from IgM12, IgM22, IgM42 and IgM46. Compositions for use in treatment of white matter disease or injury in infants, particularly PVL are provided. The invention provides methods for alleviation of neuromotor or neurodevelopmental deficits associated with neonatal hypoxia and associated with white matter injury, including PVL, in an infant.Type: ApplicationFiled: November 6, 2015Publication date: December 14, 2017Inventors: Jens O. Watzlawik, Arthur E. Warrington, Moses Rodriguez, William A. Carey
-
Patent number: 9751943Abstract: Antibodies, and particularly human antibodies, are disclosed that demonstrate activity in the treatment of demyelinating diseases as well as other diseases of the central nervous system that are of viral, bacterial or idiopathic origin, including neural dysfunction caused by spinal cord injury. Neuromodulatory agents are set forth that include and comprise a material selected from the group consisting of an antibody capable of binding structures or cells in the central nervous system, a peptide analog, a hapten, active fragments thereof, agonists thereof, mimics thereof, monomers thereof and combinations thereof. Methods are described for treating demyelinating diseases, and diseases of the central nervous system of humans and domestic animals, using polyclonal IgM antibodies and human monoclonal antibodies sHIgm22(LYM 22), sHIgm46(LYM46) ebvHIgM MSI19D10, CB2bG8, AKJR4, CB2iE12, CB2iE7, MSI19E5 and MSI10E10, active fragments thereof and the like.Type: GrantFiled: January 23, 2015Date of Patent: September 5, 2017Assignees: ACORDA THERAPEUTICS, INC., MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCHInventors: Elliott A. Gruskin, Arthur E. Warrington, Allan J. Bieber, Moses Rodriguez, Eric Walter Theodore Chojnicki
-
Publication number: 20170014490Abstract: This document relates to methods and materials involved in treating and/or preventing and/or reducing the severity of a viral infection present in a mammal. For example, methods and materials for reducing the severity of a viral infection present in a mammal (e.g., a human) are provided.Type: ApplicationFiled: July 28, 2016Publication date: January 19, 2017Inventors: Moses Rodriguez, Allan J. Bieber, Arthur E. Warrington, Jr., Meghan McGee Painter, Eric M. Poeschla
-
Patent number: 9421242Abstract: This document relates to methods and materials involved in treating and/or preventing and/or reducing the severity of a viral infection present in a mammal. For example, methods for increasing expression of an Oas gene family polypeptide, an Ifit gene family polypeptide, an Isg15 polypeptide, a Rig-1 polypeptide, a Mda5 polypeptide, and a Mx1 polypeptide in mammals using a lentiviral vector comprising nucleic acid encoding a picornavirus 3Dpol polypeptide (or a fragment thereof) are provided.Type: GrantFiled: January 15, 2014Date of Patent: August 23, 2016Assignee: Mayo Foundation for Medical Education and ResearchInventors: Moses Rodriguez, Allan J. Bieber, Arthur E. Warrington, Jr., Meghan McGee Painter, Eric M. Poeschla
-
Publication number: 20150299316Abstract: Antibodies, and particularly human antibodies, are disclosed that demonstrate activity in the treatment of demyelinating diseases as well as other diseases of the central nervous system that are of viral, bacterial or idiopathic origin, including neural dysfunction caused by spinal cord injury. Neuromodulatory agents are set forth that include and comprise a material selected from the group consisting of an antibody capable of binding structures or cells in the central nervous system, a peptide analog, a hapten, active fragments thereof, agonists thereof, mimics thereof, monomers thereof and combinations thereof. Methods are described for treating demyelinating diseases, and diseases of the central nervous system of humans and domestic animals, using polyclonal IgM antibodies and human monoclonal antibodies sHIgm22(LYM 22), sHIgm46(LYM46) ebvHIgM MSI19D10, CB2bG8, AKJR4, CB2iE12, CB2iE7, MSI19E5 and MSI10E10, active fragments thereof and the like.Type: ApplicationFiled: January 23, 2015Publication date: October 22, 2015Inventors: Elliott A. Gruskin, Arthur E. Warrington, Allan J. Bieber, Moses Rodriguez, Eric Walter Theodore Chojnicki
-
Publication number: 20150104460Abstract: Specific binding members, particularly human antibodies, particularly recombinant antibodies, and fragments thereof, which are capable of binding to and recognizing neurons in the CNS and eliciting responses in CNS neurons are provided. The antibodies are useful in the diagnosis and treatment of conditions associated with nerve damage, injury or degeneration and neurodegenerative disease, and in particular in the treatment or alleviation of stroke or cerebral ischemia. The antibodies, variable regions or CDR domain sequences thereof, and fragments thereof of the invention may also be used in therapy in combination with chemotherapeutics, immune modulators, or neuroactive agents and/or with other antibodies or fragments thereof. The antibodies or active fragments thereof may be used in therapy for stroke or cerebral ischemia alone or in combination with thrombolytics such as TPA. Antibodies are exemplified by the antibodies IgM12 and IgM42 whose sequences are provided herein.Type: ApplicationFiled: April 17, 2013Publication date: April 16, 2015Inventors: Moses Rodriguez, Arthur E. Warrington, Larry R. Pease
-
Patent number: 8968735Abstract: Antibodies, and particularly human antibodies, are disclosed that demonstrate activity in the treatment of demyelinating diseases as well as other diseases of the central nervous system that are of viral, bacterial or idiopathic origin, including neural dysfunction caused by spinal cord injury. Neuromodulatory agents are set forth that include and comprise a material selected from the group consisting of an antibody capable of binding structures or cells in the central nervous system, a peptide analog, a hapten, active fragments thereof, agonists thereof, mimics thereof, monomers thereof and combinations thereof. Methods are described for treating demyelinating diseases, and diseases of the central nervous system of humans and domestic animals, using polyclonal IgM antibodies and human monoclonal antibodies sHIgm22(LYM 22), sHIgm46(LYM46) ebvHIgM MSI19D10, CB2bG8, AKJR4, CB2iE12, CB2iE7, MSI19E5 and MSI10E10, active fragments thereof and the like.Type: GrantFiled: March 7, 2013Date of Patent: March 3, 2015Assignees: Mayo Foundation for Medical Education & Research, Acorda Therapeutics, Inc.Inventors: Elliot A. Gruskin, Eric Chojnicki, Arthur E. Warrington, Allan J. Bieber, Moses Rodriguez
-
Publication number: 20140206754Abstract: This document relates to methods and materials involved in treating and/or preventing and/or reducing the severity of a viral infection present in a mammal. For example, methods and materials for reducing the severity of a viral infection present in a mammal (e.g., a human) are provided.Type: ApplicationFiled: January 15, 2014Publication date: July 24, 2014Inventors: Moses Rodriguez, Allan J. Bieber, Arthur E. Warrington, JR., Meghan McGee Painter
-
Publication number: 20130309240Abstract: Antibodies, and particularly human antibodies, are disclosed that demonstrate activity in the treatment of demyelinating diseases as well as other diseases of the central nervous system that are of viral, bacterial or idiopathic origin, including neural dysfunction caused by spinal cord injury. Neuromodulatory agents are set forth that include and comprise a material selected from the group consisting of an antibody capable of binding structures or cells in the central nervous system, a peptide analog, a hapten, active fragments thereof, agonists thereof, mimics thereof, monomers thereof and combinations thereof. Methods are described for treating demyelinating diseases, and diseases of the central nervous system of humans and domestic animals, using polyclonal IgM antibodies and human monoclonal antibodies sHIgm22(LYM 22), sHIgm46(LYM46) ebvHIgM MSI19D10, CB2bG8, AKJR4, CB2iE12, CB2iE7, MSI19E5 and MSI10E10, active fragments thereof and the like.Type: ApplicationFiled: March 7, 2013Publication date: November 21, 2013Inventors: Elliot A. Gruskin, Eric Chojnicki, Arthur E. Warrington, Allan J. Bieber, Moses Rodriguez
-
Publication number: 20130280167Abstract: Specific binding members, particularly human antibodies, particularly recombinant antibodies, and fragments thereof, which are capable of binding to and recognizing neurons in the CNS and eliciting responses in CNS neurons are provided. The antibodies are useful for neuroprotection and in the diagnosis and treatment of conditions associated with nerve damage, injury or degeneration and neurodegenerative disease. The antibodies, variable regions or CDR domain sequences thereof, and fragments thereof of the invention may also be used in therapy in combination with chemotherapeutics, immune modulators, or neuroactive agents and/or with other antibodies or fragments thereof. Antibodies are exemplified by the antibodies IgM12 and IgM42 whose sequences are provided herein.Type: ApplicationFiled: October 19, 2011Publication date: October 24, 2013Inventors: Moses Rodriguez, Arthur E. Warrington, Larry R. Pease
-
Patent number: 8460665Abstract: Antibodies, and particularly human antibodies, are disclosed that demonstrate activity in the treatment of demyelinating diseases as well as other diseases of the central nervous system that are of viral, bacterial or idiopathic origin, including neural dysfunction caused by spinal cord injury. Neuromodulatory agents are set forth that include and comprise a material selected from the group consisting of an antibody capable of binding structures or cells in the central nervous system, a peptide analog, a hapten, active fragments thereof, agonists thereof, mimics thereof, monomers thereof and combinations thereof. Methods are described for treating demyelinating diseases, and diseases of the central nervous system of humans and domestic animals, using polyclonal IgM antibodies and human monoclonal antibodies sHIgm22(LYM 22), sHIgm46(LYM46) ebvHIgM MSI19D10, CB2bG8, AKJR4, CB2iE12, CB2iE7, MSI19E5 and MSI10E10, active fragments thereof and the like.Type: GrantFiled: May 17, 2004Date of Patent: June 11, 2013Assignees: Mayo Foundation for Medical Education and Research, Acorda Therapeutics, Inc.Inventors: Elliot A. Gruskin, Eric Chojnicki, Arthur E. Warrington, Allan J. Bieber, Moses Rodriguez
-
Publication number: 20110027288Abstract: Materials and methods for identifying human natural anti-A? autoantibodies, as well as materials and methods for using such antibodies to treat Alzheimer's disease.Type: ApplicationFiled: March 24, 2009Publication date: February 3, 2011Inventors: Moses Rodriguez, Larry R. Pease, Arthur E. Warrington, Nilufer Taner